The European Commission expanded Hympavzi approval to patients 12 and older with hemophilia A or B with inhibitors. Phase 3 data showed a 93% reduction in mean treated annualized bleeding rate versus on-demand therapy.
Meta-analysis of 23 trials finds neoadjuvant chemoimmunotherapy achieved 66% major pathologic response in head and neck cancer patients compared to 18% for dual-agent and 6% for single-agent immunotherapy, though survival impact remains unclear.
The FDA approved Tecvayli plus Darzalex Faspro for relapsed/refractory multiple myeloma in March 2026, and Darzalex Faspro-based quadruplet D-VRd for newly diagnosed transplant-ineligible patients in January 2026.
The FDA has accepted New Drug Applications for rusfertide in polycythemia vera with Priority Review and tirabrutinib for relapsed/refractory primary CNS lymphoma under Accelerated Approval, with PDUFA dates set for Q3 2026 and December 2026 respectively.
The U.S. recorded 2,280 measles cases in 2025, the highest since 1991, with 982 cases already confirmed in early 2026. North London faces an outbreak with 34 children infected in Enfield, while Philadelphia issued an exposure alert for the international airport.
The FDA accepted a new drug application for tirabrutinib to treat relapsed or refractory primary central nervous system lymphoma, with a decision expected December 18, 2026. The application is supported by phase 2 trial data showing a 67% overall response rate.
A measles exposure occurred on February 18 at Nemours Children's Hospital emergency department in Delaware. State health officials are conducting contact tracing and urging unvaccinated exposed individuals to receive MMR vaccine within 72 hours.
Soleno Therapeutics provided updates on its VYKAT XR commercial launch for Prader-Willi syndrome, reporting reimbursement progress across nearly 48 Medicaid programs and over 600 prescribers, while European regulatory review continues for approximately 9,500 additional patients.
The FDA approved pembrolizumab (Keytruda) and Keytruda Qlex plus paclitaxel, with or without bevacizumab, for adults with PD-L1+ platinum-resistant ovarian carcinoma based on Phase 3 trial data showing improved survival outcomes.
Measles cases are rising across multiple states, with over 40 cases at a Florida college and 18 cases in North Carolina since December. Federal health officials are urging vaccination as the U.S. recorded 2,280 cases in 2025.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07476807 |
Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study |
ENROLLING_BY_INVITATION | NA |
| NCT05461456 |
Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1% |
COMPLETED | PHASE1 |
| NCT05247333 |
Implementation of a Minor Ailment Service in Community Pharmacy Practice |
COMPLETED | NA |
| NCT02326467 |
Pilot Study: Safety of Chlorhexidine (CHG) Baths in Patients Less Than 2 Months of Age |
COMPLETED | PHASE1 |
| NCT01692626 |
1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX |
TERMINATED | PHASE2 |
| NCT00667589 |
Sorafenib-induced Hand- Foot Skin Reaction Treatment |
TERMINATED | PHASE2 |
| NCT00473083 |
Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer |
COMPLETED | PHASE2 |
| NCT00343187 |
A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash |
TERMINATED | PHASE2 |
